<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04481204</url>
  </required_header>
  <id_info>
    <org_study_id>2020-0075</org_study_id>
    <secondary_id>NCI-2020-04886</secondary_id>
    <secondary_id>2020-0075</secondary_id>
    <secondary_id>P30CA016672</secondary_id>
    <nct_id>NCT04481204</nct_id>
  </id_info>
  <brief_title>New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Cancer, PIONEER-Panc Study</brief_title>
  <official_title>PIONEER-Panc: Phase II Investigations of New and Emerging Therapies for Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase II study using the Bayesian platform design. There are three clinical stage&#xD;
      groups of localized pancreatic cancer: resectable, borderline resectable, and locally&#xD;
      advanced disease. Each stage group will have a defined standard of care chemotherapy regimen&#xD;
      for a control arm, serving as a basis of comparison. Each group may have one or more&#xD;
      experimental arms. Experimental arms may be added to the platform over time, and the effects&#xD;
      of the experimental treatments will be tested against the controls for each group.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To estimate major pathological response rate. (Resectable and borderline resectable groups&#xD;
      [treatment naive or previously treated]) II. To estimate 6-month disease control rate.&#xD;
      (Locally advanced groups [treatment naive or previously treated])&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To measure progression free survival and overall survival. (Resectable and borderline&#xD;
      resectable groups [treatment naive or previously treated]) II. To measure progression free&#xD;
      survival and overall survival. (Locally advanced groups [treatment naive or previously&#xD;
      treated])&#xD;
&#xD;
      EXPLORATORY OBJECTIVES:&#xD;
&#xD;
      I. To benchmark tissue acquisition protocols for deoxyribonucleic acid (DNA) and ribonucleic&#xD;
      acid (RNA) analysis in pancreatic ductal adenocarcinoma (PDAC).&#xD;
&#xD;
      II. To demonstrate concordance of cell free DNA detected mutations to those detected in the&#xD;
      tumor-derived DNA in PDAC.&#xD;
&#xD;
      III. To demonstrate response through exosome and circulating tumor DNA. IV. To demonstrate&#xD;
      response through the quantification of the immune activation by analyzing T and B cells,&#xD;
      peripheral blood mononuclear cells, and tissue biopsies.&#xD;
&#xD;
      V. To derive organoids from human PDAC and measure drug response in vitro. VI. To analyze the&#xD;
      tumor microenvironment through immunohistochemistry (IHC) and hypoxia staining.&#xD;
&#xD;
      VII. To associate prognosis of patients with baseline and follow-up quantitative computed&#xD;
      tomography (CT) image based analysis.&#xD;
&#xD;
      VIII. To associate clinical and pathological outcomes of patients with changes in radiomic&#xD;
      measurements.&#xD;
&#xD;
      IX. To correlate quality of life for patients on standard and experimental therapies with&#xD;
      laboratory, radiological, pathological, and clinical characteristics.&#xD;
&#xD;
      OUTLINE:Patients are assigned to different groups, and each group has a control arm. Within&#xD;
      each group, the patient will be randomized to the appropriate control or an experimental arm.&#xD;
      The control arms for the groups are:&#xD;
&#xD;
      Control arm for Group I (Treatment-naive resectable PDAC): Patients receive fluorouracil,&#xD;
      irinotecan, leucovorin, and oxaliplatin (mFOLFIRINOX) for 3 months before and after surgery&#xD;
      in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Control arm for Group II (Previously-treated resectable PDAC): Patients receive gemcitabine,&#xD;
      gemcitabine and nab-paclitaxel, gemcitabine and cisplatin, or FOLFIRINOX for up to 4 months&#xD;
      in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Control arm for Group III (Treatment-naive borderline resectable PDAC): Patients receive&#xD;
      FOLFIRINOX for 4-6 months in the absence of disease progression or unacceptable toxicity.&#xD;
      Patients may then undergo radiation therapy at the discretion of medical doctors.&#xD;
&#xD;
      Control arm for Group IV (Previously-treated borderline resectable PDAC): Patients receive&#xD;
      gemcitabine, gemcitabine and nab-paclitaxel, gemcitabine and cisplatin, or FOLFIRINOX for 6&#xD;
      months in the absence of disease progression or unacceptable toxicity. Patients may then&#xD;
      undergo radiation therapy at the discretion of medical doctors.&#xD;
&#xD;
      Control arm for Group V (Treatment-naive locally advanced PDAC): Patients receive FOLFIRINOX&#xD;
      for 4-6 months in the absence of disease progression or unacceptable toxicity. Patients may&#xD;
      then undergo radiation therapy at the discretion of medical doctors.&#xD;
&#xD;
      Control arm for Group VI (Previously-treated locally advanced PDAC): Patients receive&#xD;
      gemcitabine, gemcitabine and nab-paclitaxel, gemcitabine and cisplatin, or FOLFIRINOX for 6&#xD;
      months in the absence of disease progression or unacceptable toxicity. Patients may then&#xD;
      undergo radiation therapy at the discretion of medical doctors.&#xD;
&#xD;
      After completion of study treatment, patients are followed up every 16 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 30, 2020</start_date>
  <completion_date type="Anticipated">April 6, 2025</completion_date>
  <primary_completion_date type="Anticipated">April 6, 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Major pathological response rate</measure>
    <time_frame>12 weeks</time_frame>
    <description>Major pathological response is any patient who has grade I or II treatment response. Grade I - 0% residual tumor cells in the specimen (pathologic complete response, grade II - 1 to &lt; 5% residual tumor cells in the specimen.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Disease control rate</measure>
    <time_frame>6 months</time_frame>
    <description>Measured as the proportion of patients without progression.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>From the date of treatment initiation to the date of disease progression, recurrence after surgery or death from any cause whichever occurs first, assessed up to 5 years</time_frame>
    <description>Will be estimated using the Kaplan-Meier method. Comparisons of these time-to-event endpoints by important covariate subgroups will be made using the log-rank tests. Cox proportional hazards regression models will be explored to evaluate the associations between the time-to-event endpoints and covariates of interest.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>From treatment start till death or last follow-up if the patient is alive, assessed up to 5 years</time_frame>
    <description>Will be estimated using the Kaplan-Meier method. Comparisons of these time-to-event endpoints by important covariate subgroups will be made using the log-rank tests. Cox proportional hazards regression models will be explored to evaluate the associations between the time-to-event endpoints and covariates of interest.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">105</enrollment>
  <condition>Borderline Resectable Pancreatic Adenocarcinoma</condition>
  <condition>Locally Advanced Pancreatic Ductal Adenocarcinoma</condition>
  <condition>Resectable Pancreatic Ductal Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Control arm GroupI(mFOLFIRINOX)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive mFOLFIRINOX for 3 months before and after surgery in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control arm GroupII(chemotherapy, FOLFIRINOX)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive gemcitabine, gemcitabine and nab-paclitaxel, gemcitabine and cisplatin, or FOLFIRINOX for up to 4 months in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control arm GroupIII(FOLFIRINOX, radiation therapy)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive FOLFIRINOX for 4-6 months in the absence of disease progression or unacceptable toxicity. Patients may then undergo radiation therapy at the discretion of medical doctors.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control arm GroupIV(chemotherapy,FOLFIRINOX,radiation therapy)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive gemcitabine, gemcitabine and nab-paclitaxel, gemcitabine and cisplatin, or FOLFIRINOX for 6 months in the absence of disease progression or unacceptable toxicity. Patients may then undergo radiation therapy at the discretion of medical doctors.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control arm GroupV(FOLFIRINOX, radiation therapy)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive FOLFIRINOX for 4-6 months in the absence of disease progression or unacceptable toxicity. Patients may then undergo radiation therapy at the discretion of medical doctors</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control arm GroupVI(chemotherapy,FOLFIRINOX,radiation therapy)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive gemcitabine, gemcitabine and nab-paclitaxel, gemcitabine and cisplatin, or FOLFIRINOX for 6 months in the absence of disease progression or unacceptable toxicity. Patients may then undergo radiation therapy at the discretion of medical doctors</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Control arm GroupII(chemotherapy, FOLFIRINOX)</arm_group_label>
    <arm_group_label>Control arm GroupIV(chemotherapy,FOLFIRINOX,radiation therapy)</arm_group_label>
    <arm_group_label>Control arm GroupVI(chemotherapy,FOLFIRINOX,radiation therapy)</arm_group_label>
    <other_name>Abiplatin</other_name>
    <other_name>Blastolem</other_name>
    <other_name>Briplatin</other_name>
    <other_name>CDDP</other_name>
    <other_name>Cis-diammine-dichloroplatinum</other_name>
    <other_name>Cis-diamminedichloridoplatinum</other_name>
    <other_name>Cis-diamminedichloro Platinum (II)</other_name>
    <other_name>Cis-diamminedichloroplatinum</other_name>
    <other_name>Cis-dichloroammine Platinum (II)</other_name>
    <other_name>Cis-platinous Diamine Dichloride</other_name>
    <other_name>Cis-platinum</other_name>
    <other_name>Cis-platinum II</other_name>
    <other_name>Cis-platinum II Diamine Dichloride</other_name>
    <other_name>Cismaplat</other_name>
    <other_name>Cisplatina</other_name>
    <other_name>Cisplatinum</other_name>
    <other_name>Cisplatyl</other_name>
    <other_name>Citoplatino</other_name>
    <other_name>Citosin</other_name>
    <other_name>Cysplatyna</other_name>
    <other_name>DDP</other_name>
    <other_name>Lederplatin</other_name>
    <other_name>Metaplatin</other_name>
    <other_name>Neoplatin</other_name>
    <other_name>Peyrone''s Chloride</other_name>
    <other_name>Peyrone''s Salt</other_name>
    <other_name>Placis</other_name>
    <other_name>Plastistil</other_name>
    <other_name>Platamine</other_name>
    <other_name>Platiblastin</other_name>
    <other_name>Platiblastin-S</other_name>
    <other_name>Platinex</other_name>
    <other_name>Platinol</other_name>
    <other_name>Platinol- AQ</other_name>
    <other_name>Platinol-AQ</other_name>
    <other_name>Platinol-AQ VHA Plus</other_name>
    <other_name>Platinoxan</other_name>
    <other_name>Platinum</other_name>
    <other_name>Platinum Diamminodichloride</other_name>
    <other_name>Platiran</other_name>
    <other_name>Platistin</other_name>
    <other_name>Platosin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluorouracil</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Control arm GroupI(mFOLFIRINOX)</arm_group_label>
    <arm_group_label>Control arm GroupII(chemotherapy, FOLFIRINOX)</arm_group_label>
    <arm_group_label>Control arm GroupIII(FOLFIRINOX, radiation therapy)</arm_group_label>
    <arm_group_label>Control arm GroupIV(chemotherapy,FOLFIRINOX,radiation therapy)</arm_group_label>
    <arm_group_label>Control arm GroupV(FOLFIRINOX, radiation therapy)</arm_group_label>
    <arm_group_label>Control arm GroupVI(chemotherapy,FOLFIRINOX,radiation therapy)</arm_group_label>
    <other_name>5 Fluorouracil</other_name>
    <other_name>5 Fluorouracilum</other_name>
    <other_name>5 FU</other_name>
    <other_name>5-Fluoro-2,4(1H, 3H)-pyrimidinedione</other_name>
    <other_name>5-Fluorouracil</other_name>
    <other_name>5-Fluracil</other_name>
    <other_name>5-Fu</other_name>
    <other_name>5FU</other_name>
    <other_name>AccuSite</other_name>
    <other_name>Carac</other_name>
    <other_name>Fluoro Uracil</other_name>
    <other_name>Fluouracil</other_name>
    <other_name>Flurablastin</other_name>
    <other_name>Fluracedyl</other_name>
    <other_name>Fluracil</other_name>
    <other_name>Fluril</other_name>
    <other_name>Fluroblastin</other_name>
    <other_name>Ribofluor</other_name>
    <other_name>Ro 2-9757</other_name>
    <other_name>Ro-2-9757</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Control arm GroupII(chemotherapy, FOLFIRINOX)</arm_group_label>
    <arm_group_label>Control arm GroupIV(chemotherapy,FOLFIRINOX,radiation therapy)</arm_group_label>
    <arm_group_label>Control arm GroupVI(chemotherapy,FOLFIRINOX,radiation therapy)</arm_group_label>
    <other_name>dFdC</other_name>
    <other_name>dFdCyd</other_name>
    <other_name>Difluorodeoxycytidine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Control arm GroupI(mFOLFIRINOX)</arm_group_label>
    <arm_group_label>Control arm GroupII(chemotherapy, FOLFIRINOX)</arm_group_label>
    <arm_group_label>Control arm GroupIII(FOLFIRINOX, radiation therapy)</arm_group_label>
    <arm_group_label>Control arm GroupIV(chemotherapy,FOLFIRINOX,radiation therapy)</arm_group_label>
    <arm_group_label>Control arm GroupV(FOLFIRINOX, radiation therapy)</arm_group_label>
    <arm_group_label>Control arm GroupVI(chemotherapy,FOLFIRINOX,radiation therapy)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leucovorin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Control arm GroupI(mFOLFIRINOX)</arm_group_label>
    <arm_group_label>Control arm GroupII(chemotherapy, FOLFIRINOX)</arm_group_label>
    <arm_group_label>Control arm GroupIII(FOLFIRINOX, radiation therapy)</arm_group_label>
    <arm_group_label>Control arm GroupIV(chemotherapy,FOLFIRINOX,radiation therapy)</arm_group_label>
    <arm_group_label>Control arm GroupV(FOLFIRINOX, radiation therapy)</arm_group_label>
    <arm_group_label>Control arm GroupVI(chemotherapy,FOLFIRINOX,radiation therapy)</arm_group_label>
    <other_name>Folinic acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nab-paclitaxel</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Control arm GroupII(chemotherapy, FOLFIRINOX)</arm_group_label>
    <arm_group_label>Control arm GroupIV(chemotherapy,FOLFIRINOX,radiation therapy)</arm_group_label>
    <arm_group_label>Control arm GroupVI(chemotherapy,FOLFIRINOX,radiation therapy)</arm_group_label>
    <other_name>ABI 007</other_name>
    <other_name>ABI-007</other_name>
    <other_name>Abraxane</other_name>
    <other_name>Albumin-bound Paclitaxel</other_name>
    <other_name>Albumin-Stabilized Nanoparticle Paclitaxel</other_name>
    <other_name>Nanoparticle Albumin-bound Paclitaxel</other_name>
    <other_name>Nanoparticle Paclitaxel</other_name>
    <other_name>Paclitaxel Albumin</other_name>
    <other_name>paclitaxel albumin-stabilized nanoparticle formulation</other_name>
    <other_name>Protein-bound Paclitaxel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Control arm GroupI(mFOLFIRINOX)</arm_group_label>
    <arm_group_label>Control arm GroupII(chemotherapy, FOLFIRINOX)</arm_group_label>
    <arm_group_label>Control arm GroupIII(FOLFIRINOX, radiation therapy)</arm_group_label>
    <arm_group_label>Control arm GroupIV(chemotherapy,FOLFIRINOX,radiation therapy)</arm_group_label>
    <arm_group_label>Control arm GroupV(FOLFIRINOX, radiation therapy)</arm_group_label>
    <arm_group_label>Control arm GroupVI(chemotherapy,FOLFIRINOX,radiation therapy)</arm_group_label>
    <other_name>1-OHP</other_name>
    <other_name>Ai Heng</other_name>
    <other_name>Aiheng</other_name>
    <other_name>Dacotin</other_name>
    <other_name>Dacplat</other_name>
    <other_name>Diaminocyclohexane Oxalatoplatinum</other_name>
    <other_name>Eloxatin</other_name>
    <other_name>Eloxatine</other_name>
    <other_name>JM-83</other_name>
    <other_name>Oxalatoplatin</other_name>
    <other_name>Oxalatoplatinum</other_name>
    <other_name>RP 54780</other_name>
    <other_name>RP-54780</other_name>
    <other_name>SR-96669</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation Therapy</intervention_name>
    <description>Undergo RT</description>
    <arm_group_label>Control arm GroupIII(FOLFIRINOX, radiation therapy)</arm_group_label>
    <arm_group_label>Control arm GroupIV(chemotherapy,FOLFIRINOX,radiation therapy)</arm_group_label>
    <arm_group_label>Control arm GroupV(FOLFIRINOX, radiation therapy)</arm_group_label>
    <arm_group_label>Control arm GroupVI(chemotherapy,FOLFIRINOX,radiation therapy)</arm_group_label>
    <other_name>Cancer Radiotherapy</other_name>
    <other_name>Irradiate</other_name>
    <other_name>Irradiated</other_name>
    <other_name>Irradiation</other_name>
    <other_name>Radiation</other_name>
    <other_name>Radiation Therapy, NOS</other_name>
    <other_name>Radiotherapeutics</other_name>
    <other_name>Radiotherapy</other_name>
    <other_name>RT</other_name>
    <other_name>Therapy, Radiation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  TREATMENT NAIVE RESECTABLE PDAC COHORT: Pathologically proven adenocarcinoma of the&#xD;
             pancreas by cytology or biopsy&#xD;
&#xD;
          -  TREATMENT NAIVE RESECTABLE PDAC COHORT: Confirmation of clinical stage of resectable&#xD;
&#xD;
          -  TREATMENT NAIVE RESECTABLE PDAC COHORT: No prior chemotherapy or radiation therapy for&#xD;
             PDAC&#xD;
&#xD;
          -  TREATMENT NAIVE RESECTABLE PDAC COHORT: No current use of immunosuppressive medication&#xD;
&#xD;
          -  TREATMENT NAIVE RESECTABLE PDAC COHORT: Not pregnant and not nursing, for women of&#xD;
             childbearing potential, a negative urine or blood pregnancy test done =&lt; 7 days prior&#xD;
             to registration is required&#xD;
&#xD;
          -  TREATMENT NAIVE RESECTABLE PDAC COHORT: Life expectancy greater than 6 months&#xD;
&#xD;
          -  TREATMENT NAIVE RESECTABLE PDAC COHORT: Eastern Cooperative Oncology Group (ECOG)&#xD;
             performance status 0 or 1&#xD;
&#xD;
          -  TREATMENT NAIVE RESECTABLE PDAC COHORT: Absolute neutrophil count (ANC) &gt;= 1,500/mm^3&#xD;
&#xD;
          -  TREATMENT NAIVE RESECTABLE PDAC COHORT: Platelet count &gt;= 100,000/mm^3&#xD;
&#xD;
          -  TREATMENT NAIVE RESECTABLE PDAC COHORT: Creatinine =&lt; 1.5 x upper limit of normal&#xD;
             (ULN)&#xD;
&#xD;
          -  TREATMENT NAIVE RESECTABLE PDAC COHORT: Calculated (Calc.) creatinine clearance &gt; 45&#xD;
             mL/min&#xD;
&#xD;
          -  TREATMENT NAIVE RESECTABLE PDAC COHORT: Total bilirubin =&lt; 2.0 mg/dL&#xD;
&#xD;
          -  TREATMENT NAIVE RESECTABLE PDAC COHORT: Aspartate aminotransferase (AST)/alanine&#xD;
             aminotransferase (ALT) =&lt; 2.5 x upper limit of normal (ULN)&#xD;
&#xD;
          -  TREATMENT NAIVE RESECTABLE PDAC COHORT: Hemoglobin &gt;= 8.0 mg/dL&#xD;
&#xD;
          -  PREVIOUSLY TREATED RESECTABLE PDAC COHORT: Pathologically proven adenocarcinoma of the&#xD;
             pancreas by cytology or biopsy&#xD;
&#xD;
          -  PREVIOUSLY TREATED RESECTABLE PDAC COHORT: Confirmation of clinical stage of&#xD;
             resectable&#xD;
&#xD;
          -  PREVIOUSLY TREATED RESECTABLE PDAC COHORT: Prior chemotherapy for PDAC is allowed, as&#xD;
             long as the regimen is considered a standard regimen for PDAC (e.g., gemcitabine,&#xD;
             gemcitabine-cisplatin, gemcitabine/nab-paclitaxel, gemcitabine/capecitabine,&#xD;
             FOLFIRINOX). This should be discussed with the study principal investigators (PIs)&#xD;
             prior to enrollment to ensure the regimen for a given patient is acceptable&#xD;
&#xD;
          -  PREVIOUSLY TREATED RESECTABLE PDAC COHORT: No current use of immunosuppressive&#xD;
             medication&#xD;
&#xD;
          -  PREVIOUSLY TREATED RESECTABLE PDAC COHORT: Not pregnant and not nursing, For women of&#xD;
             childbearing potential, a negative urine or blood pregnancy test done ≤ 7 days prior&#xD;
             to registration is required&#xD;
&#xD;
          -  PREVIOUSLY TREATED RESECTABLE PDAC COHORT: Life expectancy greater than 6 months&#xD;
&#xD;
          -  PREVIOUSLY TREATED RESECTABLE PDAC COHORT: ECOG performance status 0 or 1&#xD;
&#xD;
          -  PREVIOUSLY TREATED RESECTABLE PDAC COHORT: Absolute neutrophil count (ANC) &gt;=&#xD;
             1,500/mm^3&#xD;
&#xD;
          -  PREVIOUSLY TREATED RESECTABLE PDAC COHORT: Platelet count &gt;= 100,000/mm^3&#xD;
&#xD;
          -  PREVIOUSLY TREATED RESECTABLE PDAC COHORT: Creatinine =&lt; 1.5 x upper limit of normal&#xD;
             (ULN)&#xD;
&#xD;
          -  PREVIOUSLY TREATED RESECTABLE PDAC COHORT: Calc. creatinine clearance &gt; 45 mL/min&#xD;
&#xD;
          -  PREVIOUSLY TREATED RESECTABLE PDAC COHORT: Total bilirubin =&lt; 2.0 mg/dL&#xD;
&#xD;
          -  PREVIOUSLY TREATED RESECTABLE PDAC COHORT: AST/ALT =&lt; 2.5 x upper limit of normal&#xD;
             (ULN)&#xD;
&#xD;
          -  PREVIOUSLY TREATED RESECTABLE PDAC COHORT: Hemoglobin &gt;= 8.0 mg/dL&#xD;
&#xD;
          -  TREATMENT NAIVE BORDERLINE RESECTABLE PDAC COHORT: Pathologically proven&#xD;
             adenocarcinoma of the pancreas by cytology or biopsy&#xD;
&#xD;
          -  TREATMENT NAIVE BORDERLINE RESECTABLE PDAC COHORT: Confirmation of clinical stage of&#xD;
             borderline resectable&#xD;
&#xD;
          -  TREATMENT NAIVE BORDERLINE RESECTABLE PDAC COHORT: No prior chemotherapy or radiation&#xD;
             therapy for PDAC&#xD;
&#xD;
          -  TREATMENT NAIVE BORDERLINE RESECTABLE PDAC COHORT: No current use of immunosuppressive&#xD;
             medication&#xD;
&#xD;
          -  TREATMENT NAIVE BORDERLINE RESECTABLE PDAC COHORT: Not pregnant and not nursing, For&#xD;
             women of childbearing potential, a negative urine or blood pregnancy test done ≤ 7&#xD;
             days prior to registration is required&#xD;
&#xD;
          -  TREATMENT NAIVE BORDERLINE RESECTABLE PDAC COHORT: Life expectancy greater than 6&#xD;
             months&#xD;
&#xD;
          -  TREATMENT NAIVE BORDERLINE RESECTABLE PDAC COHORT: ECOG performance status 0 or 1&#xD;
&#xD;
          -  TREATMENT NAIVE BORDERLINE RESECTABLE PDAC COHORT: Absolute neutrophil count (ANC) &gt;=&#xD;
             1,500/mm^3&#xD;
&#xD;
          -  TREATMENT NAIVE BORDERLINE RESECTABLE PDAC COHORT: Platelet count &gt;= 100,000/mm^3&#xD;
&#xD;
          -  TREATMENT NAIVE BORDERLINE RESECTABLE PDAC COHORT: Creatinine =&lt; 1.5 x upper limit of&#xD;
             normal (ULN)&#xD;
&#xD;
          -  TREATMENT NAIVE BORDERLINE RESECTABLE PDAC COHORT: Calc. creatinine clearance &gt; 45&#xD;
             mL/min&#xD;
&#xD;
          -  TREATMENT NAIVE BORDERLINE RESECTABLE PDAC COHORT: Total bilirubin =&lt; 2.0 mg/dL&#xD;
&#xD;
          -  TREATMENT NAIVE BORDERLINE RESECTABLE PDAC COHORT: AST/ALT =&lt; 2.5 x upper limit of&#xD;
             normal (ULN)&#xD;
&#xD;
          -  TREATMENT NAIVE BORDERLINE RESECTABLE PDAC COHORT: Hemoglobin &gt;= 8.0 mg/dL&#xD;
&#xD;
          -  PREVIOUSLY TREATED BORDERLINE RESECTABLE PDAC COHORT: Pathologically proven&#xD;
             adenocarcinoma of the pancreas by cytology or biopsy&#xD;
&#xD;
          -  PREVIOUSLY TREATED BORDERLINE RESECTABLE PDAC COHORT: Confirmation of clinical stage&#xD;
             of borderline resectable&#xD;
&#xD;
          -  PREVIOUSLY TREATED BORDERLINE RESECTABLE PDAC COHORT: Prior chemotherapy for PDAC is&#xD;
             allowed, as long as the regimen is considered a standard regimen for PDAC (e.g.,&#xD;
             gemcitabine, gemcitabine-cisplatin, gemcitabine/nab-paclitaxel,&#xD;
             gemcitabine/capecitabine, FOLFIRINOX). This should be discussed with the study PIs&#xD;
             prior to enrollment to ensure the regimen for a given patient is acceptable&#xD;
&#xD;
          -  PREVIOUSLY TREATED BORDERLINE RESECTABLE PDAC COHORT: No current use of&#xD;
             immunosuppressive medication&#xD;
&#xD;
          -  PREVIOUSLY TREATED BORDERLINE RESECTABLE PDAC COHORT: Not pregnant and not nursing,&#xD;
             For women of childbearing potential, a negative urine or blood pregnancy test done =&lt;&#xD;
             7 days prior to registration is required&#xD;
&#xD;
          -  PREVIOUSLY TREATED BORDERLINE RESECTABLE PDAC COHORT: Life expectancy greater than 6&#xD;
             months&#xD;
&#xD;
          -  PREVIOUSLY TREATED BORDERLINE RESECTABLE PDAC COHORT: ECOG performance status 0 or 1&#xD;
&#xD;
          -  PREVIOUSLY TREATED BORDERLINE RESECTABLE PDAC COHORT: Absolute neutrophil count (ANC)&#xD;
             &gt;= 1,500/mm^3&#xD;
&#xD;
          -  PREVIOUSLY TREATED BORDERLINE RESECTABLE PDAC COHORT: Platelet count &gt;= 100,000/mm^3&#xD;
&#xD;
          -  PREVIOUSLY TREATED BORDERLINE RESECTABLE PDAC COHORT: Creatinine =&lt; 1.5 x upper limit&#xD;
             of normal (ULN)&#xD;
&#xD;
          -  PREVIOUSLY TREATED BORDERLINE RESECTABLE PDAC COHORT: Calc. creatinine clearance &gt; 45&#xD;
             mL/min&#xD;
&#xD;
          -  PREVIOUSLY TREATED BORDERLINE RESECTABLE PDAC COHORT: Total bilirubin =&lt; 2.0 mg/dL&#xD;
&#xD;
          -  PREVIOUSLY TREATED BORDERLINE RESECTABLE PDAC COHORT: AST/ALT =&lt; 2.5 x upper limit of&#xD;
             normal (ULN)&#xD;
&#xD;
          -  PREVIOUSLY TREATED BORDERLINE RESECTABLE PDAC COHORT: Hemoglobin &gt;= 8.0 mg/dL&#xD;
&#xD;
          -  TREATMENT NAIVE LOCALLY ADVANCED PDAC COHORT: Pathologically proven adenocarcinoma of&#xD;
             the pancreas by cytology or biopsy&#xD;
&#xD;
          -  TREATMENT NAIVE LOCALLY ADVANCED PDAC COHORT: Confirmation of clinical stage of&#xD;
             locally advanced&#xD;
&#xD;
          -  TREATMENT NAIVE LOCALLY ADVANCED PDAC COHORT: No prior chemotherapy or radiation&#xD;
             therapy for PDAC&#xD;
&#xD;
          -  TREATMENT NAIVE LOCALLY ADVANCED PDAC COHORT: Pregnancy and Nursing Status: Not&#xD;
             pregnant and not nursing, For women of childbearing potential, a negative urine or&#xD;
             blood pregnancy test done ≤ 7 days prior to registration is required&#xD;
&#xD;
          -  TREATMENT NAIVE LOCALLY ADVANCED PDAC COHORT: Life expectancy greater than 6 months&#xD;
&#xD;
          -  TREATMENT NAIVE LOCALLY ADVANCED PDAC COHORT: ECOG performance status 0 or 1&#xD;
&#xD;
          -  TREATMENT NAIVE LOCALLY ADVANCED PDAC COHORT: Absolute neutrophil count (ANC) &gt;=&#xD;
             1,500/mm^3&#xD;
&#xD;
          -  TREATMENT NAIVE LOCALLY ADVANCED PDAC COHORT: Platelet count &gt;= 100,000/mm^3&#xD;
&#xD;
          -  TREATMENT NAIVE LOCALLY ADVANCED PDAC COHORT: Creatinine =&lt; 1.5 x upper limit of&#xD;
             normal (ULN)&#xD;
&#xD;
          -  TREATMENT NAIVE LOCALLY ADVANCED PDAC COHORT: Calc. creatinine clearance &gt; 45 mL/min&#xD;
&#xD;
          -  TREATMENT NAIVE LOCALLY ADVANCED PDAC COHORT: Total bilirubin =&lt; 2.0 mg/dL&#xD;
&#xD;
          -  TREATMENT NAIVE LOCALLY ADVANCED PDAC COHORT: AST/ALT =&lt; 2.5 x upper limit of normal&#xD;
             (ULN)&#xD;
&#xD;
          -  TREATMENT NAIVE LOCALLY ADVANCED PDAC COHORT: Hemoglobin &gt;= 8.0 mg/dL&#xD;
&#xD;
          -  PREVIOUSLY TREATED LOCALLY ADVANCED PDAC COHORT: Pathologically proven adenocarcinoma&#xD;
             of the pancreas by cytology or biopsy&#xD;
&#xD;
          -  PREVIOUSLY TREATED LOCALLY ADVANCED PDAC COHORT: Confirmation of clinical stage of&#xD;
             locally advanced&#xD;
&#xD;
          -  PREVIOUSLY TREATED LOCALLY ADVANCED PDAC COHORT: Prior chemotherapy for PDAC is&#xD;
             allowed, as long as the regimen is considered a standard regimen for PDAC (e.g.,&#xD;
             gemcitabine, gemcitabine-cisplatin, gemcitabine/nab-paclitaxel,&#xD;
             gemcitabine/capecitabine, FOLFIRINOX). This should be discussed with the study PIs&#xD;
             prior to enrollment to ensure the regimen for a given patient is acceptable&#xD;
&#xD;
          -  PREVIOUSLY TREATED LOCALLY ADVANCED PDAC COHORT: No current use of immunosuppressive&#xD;
             medication&#xD;
&#xD;
          -  PREVIOUSLY TREATED LOCALLY ADVANCED PDAC COHORT: Not pregnant and not nursing, For&#xD;
             women of childbearing potential, a negative urine or blood pregnancy test done =&lt; 7&#xD;
             days prior to registration is required&#xD;
&#xD;
          -  PREVIOUSLY TREATED LOCALLY ADVANCED PDAC COHORT: Life expectancy greater than 6 months&#xD;
&#xD;
          -  PREVIOUSLY TREATED LOCALLY ADVANCED PDAC COHORT: ECOG performance status 0 or 1&#xD;
&#xD;
          -  PREVIOUSLY TREATED LOCALLY ADVANCED PDAC COHORT: Absolute neutrophil count (ANC) &gt;=&#xD;
             1,500/mm^3&#xD;
&#xD;
          -  PREVIOUSLY TREATED LOCALLY ADVANCED PDAC COHORT: Platelet count &gt;= 100,000/mm^3&#xD;
&#xD;
          -  PREVIOUSLY TREATED LOCALLY ADVANCED PDAC COHORT: Creatinine =&lt; 1.5 x upper limit of&#xD;
             normal (ULN)&#xD;
&#xD;
          -  PREVIOUSLY TREATED LOCALLY ADVANCED PDAC COHORT: Calc. creatinine clearance &gt; 45&#xD;
             mL/min&#xD;
&#xD;
          -  PREVIOUSLY TREATED LOCALLY ADVANCED PDAC COHORT: Total bilirubin =&lt; 2.0 mg/dL&#xD;
&#xD;
          -  PREVIOUSLY TREATED LOCALLY ADVANCED PDAC COHORT: AST/ALT =&lt; 2.5 x upper limit of&#xD;
             normal (ULN)&#xD;
&#xD;
          -  PREVIOUSLY TREATED LOCALLY ADVANCED PDAC COHORT: Hemoglobin &gt;= 8.0 mg/dL&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  TREATMENT NAIVE RESECTABLE PDAC COHORT: Previous treatment for PDAC with chemotherapy&#xD;
             or radiation&#xD;
&#xD;
          -  TREATMENT NAIVE RESECTABLE PDAC COHORT: Active malignancy, except basal cell carcinoma&#xD;
&#xD;
          -  TREATMENT NAIVE RESECTABLE PDAC COHORT: Staging other than resectable PDAC&#xD;
&#xD;
          -  TREATMENT NAIVE RESECTABLE PDAC COHORT: Known uncontrolled (grade &gt;=2) or active&#xD;
             gastric or duodenal ulcer disease within 30 days of enrollment&#xD;
&#xD;
          -  TREATMENT NAIVE RESECTABLE PDAC COHORT: Prior surgical resection of pancreatic tumor&#xD;
&#xD;
          -  TREATMENT NAIVE RESECTABLE PDAC COHORT: Known contraindication to iodine-based or&#xD;
             gadolinium-based intravenous (IV) contrast&#xD;
&#xD;
          -  TREATMENT NAIVE RESECTABLE PDAC COHORT: Clinically significant cardiac arrhythmias&#xD;
             (e.g., ventricular tachycardia, ventricular fibrillation, torsades de pointes, second&#xD;
             or third degree atrioventricular heart block without a permanent pacemaker in place)&#xD;
&#xD;
          -  TREATMENT NAIVE RESECTABLE PDAC COHORT: Class III or IV congestive heart failure as&#xD;
             defined by the New York Heart Association functional classification system &lt; 6 months&#xD;
             prior to screening&#xD;
&#xD;
          -  TREATMENT NAIVE RESECTABLE PDAC COHORT: Known active, uncontrolled (high viral load)&#xD;
             human immunodeficiency virus (HIV), hepatitis B or hepatitis C infection&#xD;
&#xD;
               -  Patients who have been vaccinated for hepatitis B and do not have a history of&#xD;
                  infection are eligible&#xD;
&#xD;
          -  TREATMENT NAIVE RESECTABLE PDAC COHORT: Female patients who are pregnant of&#xD;
             breastfeeding&#xD;
&#xD;
          -  TREATMENT NAIVE RESECTABLE PDAC COHORT: Women of child-bearing potential and their&#xD;
             male partners who are unwilling or unable to use an acceptable method of birth control&#xD;
             to avoid pregnancy for the entire study period. Acceptable methods of contraception&#xD;
             are those that, alone or in combination, result in a failure rate of &lt; 1% per year&#xD;
             when used consistently and correctly&#xD;
&#xD;
          -  TREATMENT NAIVE RESECTABLE PDAC COHORT: Have significant psychiatric, social, or&#xD;
             medical condition(s) that could increase the subject's risk, interfere with protocol&#xD;
             adherence, or affect the subject's ability to give informed consent&#xD;
&#xD;
          -  PREVIOUSLY TREATED RESECTABLE PDAC COHORT: The patient is treatment naive&#xD;
&#xD;
          -  PREVIOUSLY TREATED RESECTABLE PDAC COHORT: The patient previously received radiation&#xD;
             to the abdomen for any reason&#xD;
&#xD;
          -  PREVIOUSLY TREATED RESECTABLE PDAC COHORT: Active malignancy, except basal cell&#xD;
             carcinoma&#xD;
&#xD;
          -  PREVIOUSLY TREATED RESECTABLE PDAC COHORT: Staging other than resectable PDAC at the&#xD;
             time of diagnosis&#xD;
&#xD;
          -  PREVIOUSLY TREATED RESECTABLE PDAC COHORT: Receiving any approved or investigational&#xD;
             anti-neoplastic agent other than the chemotherapies specified in this protocol&#xD;
&#xD;
          -  PREVIOUSLY TREATED RESECTABLE PDAC COHORT: Known uncontrolled (grade &gt;= 2) or active&#xD;
             gastric or duodenal ulcer disease within 30 days of enrollment&#xD;
&#xD;
          -  PREVIOUSLY TREATED RESECTABLE PDAC COHORT: Prior surgical resection of pancreatic&#xD;
             tumor&#xD;
&#xD;
          -  PREVIOUSLY TREATED RESECTABLE PDAC COHORT: Known contraindication to iodine-based or&#xD;
             gadolinium-based IV contrast&#xD;
&#xD;
          -  PREVIOUSLY TREATED RESECTABLE PDAC COHORT: Clinically significant cardiac arrhythmias&#xD;
             (e.g., ventricular tachycardia, ventricular fibrillation, torsades de pointes, second&#xD;
             or third degree atrioventricular heart block without a permanent pacemaker in place)&#xD;
&#xD;
          -  PREVIOUSLY TREATED RESECTABLE PDAC COHORT: Class III or IV congestive heart failure as&#xD;
             defined by the New York Heart Association functional classification system &lt; 6 months&#xD;
             prior to screening&#xD;
&#xD;
          -  PREVIOUSLY TREATED RESECTABLE PDAC COHORT: Known active, uncontrolled (high viral&#xD;
             load) HIV, hepatitis B or hepatitis C infection&#xD;
&#xD;
               -  Patients who have been vaccinated for hepatitis B and do not have a history of&#xD;
                  infection are eligible&#xD;
&#xD;
          -  PREVIOUSLY TREATED RESECTABLE PDAC COHORT: Female patients who are pregnant of&#xD;
             breastfeeding&#xD;
&#xD;
          -  PREVIOUSLY TREATED RESECTABLE PDAC COHORT: Women of child-bearing potential and their&#xD;
             male partners who are unwilling or unable to use an acceptable method of birth control&#xD;
             to avoid pregnancy for the entire study period. Acceptable methods of contraception&#xD;
             are those that, alone or in combination, result in a failure rate of &lt; 1% per year&#xD;
             when used consistently and correctly&#xD;
&#xD;
          -  PREVIOUSLY TREATED RESECTABLE PDAC COHORT: Have significant psychiatric, social, or&#xD;
             medical condition(s) that could increase the subject's risk, interfere with protocol&#xD;
             adherence, or affect the subject's ability to give informed consent&#xD;
&#xD;
          -  TREATMENT NAIVE BORDERLINE RESECTABLE PDAC COHORT: Previous treatment for PDAC with&#xD;
             chemotherapy or radiation&#xD;
&#xD;
          -  TREATMENT NAIVE BORDERLINE RESECTABLE PDAC COHORT: Active malignancy, except basal&#xD;
             cell carcinoma&#xD;
&#xD;
          -  TREATMENT NAIVE BORDERLINE RESECTABLE PDAC COHORT: Staging other than borderline&#xD;
             resectable PDAC&#xD;
&#xD;
          -  TREATMENT NAIVE BORDERLINE RESECTABLE PDAC COHORT: Known uncontrolled (grade &gt;= 2) or&#xD;
             active gastric or duodenal ulcer disease within 30 days of enrollment&#xD;
&#xD;
          -  TREATMENT NAIVE BORDERLINE RESECTABLE PDAC COHORT: Prior surgical resection of&#xD;
             pancreatic tumor&#xD;
&#xD;
          -  TREATMENT NAIVE BORDERLINE RESECTABLE PDAC COHORT: Known contraindication to&#xD;
             iodine-based or gadolinium-based IV contrast&#xD;
&#xD;
          -  TREATMENT NAIVE BORDERLINE RESECTABLE PDAC COHORT: Clinically significant cardiac&#xD;
             arrhythmias (e.g., ventricular tachycardia, ventricular fibrillation, torsades de&#xD;
             pointes, second or third degree atrioventricular heart block without a permanent&#xD;
             pacemaker in place)&#xD;
&#xD;
          -  TREATMENT NAIVE BORDERLINE RESECTABLE PDAC COHORT: Class III or IV congestive hea&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eugene J Koay</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eugene J. Koay</last_name>
    <phone>713-563-2381</phone>
    <email>ekoay@mdanderson.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Eugene J. Koay</last_name>
      <phone>713-563-2381</phone>
    </contact>
    <investigator>
      <last_name>Eugene J. Koay</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>Related Info</description>
  </link>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>July 17, 2020</study_first_submitted>
  <study_first_submitted_qc>July 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 22, 2020</study_first_posted>
  <last_update_submitted>August 10, 2020</last_update_submitted>
  <last_update_submitted_qc>August 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

